CBD and Drug Interactions: What You Need to Know Before Starting
Affiliate Disclosure: This post may contain affiliate links. We may earn a commission if you purchase through our links at...
Read morePsoriasis is an autoimmune condition where the immune system overreacts, causing rapid skin cell turnover and inflammation. CBD modulates immune function by suppressing Th17 cells and other inflammatory pathways implicated in psoriasis. Research shows CBD reduces TNF-α, IL-1β, and IL-17—all key psoriasis drivers. By balancing immune response without full immunosuppression, CBD offers relief without the systemic side effects of biologic drugs.
Apply CBD cream directly to psoriatic plaques 2-3 times daily. Optimal concentrations range from 500mg-2000mg per ounce depending on severity. CBD penetrates psoriatic lesions to reduce inflammatory cytokines at source. Users report reduced plaque thickness within 2-3 weeks and significant itch relief within days. Layer CBD cream over affected areas, then apply a traditional moisturizer. For scalp psoriasis, use CBD oil or salve designed for scalp penetration.
For psoriasis affecting large body areas, oral CBD offers systemic immune support. Start with 10-15mg daily and increase to 20-30mg based on improvement. Oral CBD works alongside topical treatment—many dermatologists recommend combination therapy for best results. Full-spectrum formulas contain terpenes with additional anti-inflammatory benefits: beta-caryophyllene and limonene both support psoriasis improvement.
Stress is a major psoriasis trigger. CBD’s anxiolytic properties break the stress-flare cycle. By reducing cortisol and anxiety, CBD prevents stress-induced immune activation that worsens psoriasis. Many patients report fewer flares when using CBD regularly. The compound’s sleep-promoting effects further support immune balance—improved sleep reduces inflammation and supports skin healing overnight.

Interested in finding out more about what’s happening in the world of CBD and Medicinal Cannabis?
Head to CBD World News for the latest scientific research, clinical trials, and business news.
Abstract: Currently, there are no approved pharmacotherapies for addiction to cocaine and other psychostimulant drugs. Several studies have proposed that...
Read moreCredits: Albert Batalla†, Hella Janssen†, Shiral S. Gangadin and Matthijs G. Bossong († These authors contributed equally to this work.)...
Read moreAuthors: Kimberly A. Babson1 & James Sottile 2 & Danielle Morabito1 Publish Date: 27 March 2017 Published by: Springer Science+Business...
Read more